While 2025 began on a positive note for the pharmaceutical industry, things have taken a sharp turn amid escalating fears of a global trade war. While Trump had initially exempted pharmaceuticals from ...

Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.

Wall Street analysts said the results for Verve’s therapy appeared competitive on efficacy, while avoiding any major safety ...

With the recent developments in the atopic dermatitis (AD) market, the field is becoming more competitive as novel therapies are soon anticipated to enter the market. This evolution may benefit AD ...

A Delaware federal court has ruled against Amgen's bid to dismiss an antitrust lawsuit filed by Regeneron Pharmaceuticals Inc ...

AI-driven drug discovery firms rallied on Friday after the U.S. Food and Drug Administration (FDA) announced an initiative to ...

Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face ...

As Fierce Pharma points out, patent expirations are a routine occurrence in the pharmaceutical world, but 2025 stands out for ...

The RAINIER Study (NCT06496607) is an ongoing Phase IIa clinical trial investigating Solrikitug for adults with asthma. This randomized, double-blind, placebo-controlled study evaluates three dose ...

Celltrion gains Australian approval for three biosimilars in ophthalmology and bone disease Celltrion secures TGA endorsement ...

Trump on Tuesday said his administration will be announcing a “major” tariff on pharmaceuticals “very shortly.” ...

Trump on Tuesday said his administration will be announcing a “major” tariff on pharmaceuticals “very shortly.” ...